No Data
Pfizer Ran What Could Be the Largest Tax Dodging Scheme Among Big Pharma: Senator
Merck Subcutaneous Keytruda Gains FDA Target Date in September
Cruise Line Check: Carnival, Royal Caribbean, and Viking Attract Bull Ratings at BNP Paribas
Merck's Investigational Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Demonstrates Noninferior Pharmacokinetics Compared To Intravenous KEYTRUDA In Pivotal 3475A-D77 Trial; A Time And Motion Descriptive Analysis Shows Nearly 50% Reductions In...
RFK Jr. Reportedly Plans 10,000 Job Cuts in HHS With FDA, CDC, Medicare Affected
Domestic Innovative Drugs are once again surging towards overseas markets! Concept stocks have responded with a significant increase. Is the external authorization model the optimal choice?
① As of the time of publication, the Hang Seng Innovative Drugs Index has risen over 5%, with multiple Innovative Drugs concept stocks experiencing double-digit gains; ② In recent days, Jiangsu Hengrui Pharmaceuticals, Hepo Pharmaceutical, UNITED LAB, and other Biotech companies have issued announcements about "going abroad"; ③ Northeast Securities stated that top MNCs recognize the R&D capabilities of Chinese local companies and are more willing to assign high valuations.
